Mydecine Announces Conditional Approval of CSE Listing
Related company: Mydecine Innovations Group (https://mydecineinc.com/)
Mydecine Innovations Group has received conditional approval to list its common shares on the Canadian Securities Exchange (CSE), which will provide liquidity and reduce expenses. The company focuses on increasing physicians’ access to serotonin-modulating medicine using psychedelic substances and artificial intelligence (AI). Mydecine is developing innovative medications for various conditions and is dedicated to making them affordable and accessible. The company utilizes AI and pharma research infrastructure to develop and manufacture new medications. Mydecine’s mission is to create a positive difference in the lives of others.
Read the full article here: eagletribune.com